Telogen effluvium caused by magnesium valproate and lamotrigine [9]

Acta Dermato-Venereologica

Volumn 85, Issue 1, 2005, Pages 77-78

  Patrizi, Annalisa ^a   Savoia, Francesco ^a   Negosanti, Francesca ^a   Posar, Annio ^a   Santucci, Margherita ^a   Neri, Iria ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; LAMOTRIGINE; VALPROATE MAGNESIUM; VALPROIC ACID;

ADOLESCENT; ADULT; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HAIR ANALYSIS; HAIR LOSS; HUMAN; LETTER; MENTAL DEFICIENCY; PRIORITY JOURNAL; RASH; SKIN MANIFESTATION; TELOGEN EFFLUVIUM; TRICHOGRAM;

ACUTE DISEASE; ADOLESCENT; ADULT; ALOPECIA; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; TRIAZINES; VALPROIC ACID;

EID: 13844253308     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155550410021466     Document Type: Letter

References (6)

1. Culy CR, Goa KL. Lamotrigine. A review of its use in childhood epilepsy. Paediatr Drugs 2000; 2: 299-330.
2. Massenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf 2000; 22: 303-312.
3. Feliciani C, Verrotti A, Coscione G, Toto P, Morelli F, Di Benedetto A, et al. Skin reactions due to anti-epileptic drugs: several case-reports with long-term follow-up. Int J Immunopathol Pharmacol 2003; 16: 89-93.
4. Litt JZ. Lamotrigine. In: Drug eruption reference manual 2000, Millennium edition, DERM. New York: Parthenon Publishing Group, 2000: 314-315.
5. Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12: 35-42.
6. Despland PA. Tolerance to and unwanted effects of valproate sodium. Schweiz Rundsch Med Prax 1994; 83: 1132-1139.